BMS-986504

English name Navlimetostat

also known as Navlimetostat · MTA-cooperative PRMT5 Inhibitor BMS-986504

targets PRMT5 via inhibition

Developed for: cancer · non-small cell lung carcinoma · biliary tract cancer · carcinoma of esophagus · colon carcinoma · diffused pleural mesothelioma · gastroesophageal cancer · glioblastoma
+6 more
· malignant peripheral nerve sheath tumor · mesothelioma · metastatic carcinoma · pancreas disorder · pancreatic ductal adenocarcinoma · urothelial carcinoma
Investigated by: Bristol-Myers Squibb · M.D. Anderson Cancer Center · Ankit Mangla, MD · Memorial Sloan Kettering Cancer Center · Nader Sanai · National Cancer Institute (NCI)
+2 more
· Northwestern University · University of Southampton

Trials 13 · a red edge is where a trial was stopped

today NCT07594626 · Ph 1/2 NCT07579221 · Ph 1/2 NCT07549022 · Ph 1/2 NCT07492680 · Ph 2 NCT07283705 · Ph 2 NCT07602946 · Ph 2 NCT07544628 · Ph 1 NCT07532902 · Ph 1 NCT07076121 · Ph 2/3 NCT07077434 · Ph 1 NCT06855771 · Ph 2 NCT06883747 · Ph 0 NCT06672523 · Ph 1

202620272028202920302031

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT06883747	Apr 2025 → Sep 2026 expected	glioblastoma	Nader Sanai	Recruiting	No outcome recorded
Phase 14 trials
Phase 1	NCT07544628	Apr → Aug 2026 overdue	—	Bristol-Myers Squibb	Recruiting	No outcome recorded
Phase 1	NCT07532902	Apr 2026 → Apr 2029 expected	diffused pleural mesothelioma, gastroesophageal cancer, urothelial carcinoma	Memorial Sloan Kettering Cancer Center	Recruiting	No outcome recorded
Phase 1	NCT07077434	Oct 2025 → Jan 2027 expected	cancer	Bristol-Myers Squibb	Recruiting	No outcome recorded
Phase 1	NCT06672523	Mar 2025 → Oct 2027 expected	—	Bristol-Myers Squibb	Recruiting	No outcome recorded
Phase 1/23 trials
Phase 1/2	NCT07594626	Dec 2027 → Dec 2030 expected	biliary tract cancer, carcinoma of esophagus, colon carcinoma, metastatic carcinoma	Northwestern University	Not yet recruiting	No outcome recorded
Phase 1/2	NCT07579221	Nov 2026 → Aug 2029 expected	non-small cell lung carcinoma	M.D. Anderson Cancer Center	Not yet recruiting	No outcome recorded
Phase 1/2	NCT07549022	Aug 2026 → Apr 2028 expected	malignant peripheral nerve sheath tumor	Ankit Mangla, MD	Not yet recruiting	No outcome recorded
Phase 24 trials
Phase 2	NCT07492680	Jul 2026 → Aug 2028 expected	cancer	Bristol-Myers Squibb	Not yet recruiting	No outcome recorded
Phase 2	NCT07283705	May 2026 → Oct 2029 expected	pancreas disorder	M.D. Anderson Cancer Center	Recruiting	No outcome recorded
Phase 2	NCT07602946	May 2026 → Jul 2027 expected	mesothelioma	University of Southampton	Not yet recruiting	No outcome recorded
Phase 2	NCT06855771	Sep 2025 → Dec 2028 expected	non-small cell lung carcinoma	Bristol-Myers Squibb	Recruiting	No outcome recorded
Phase 2/31 trial
Phase 2/3	NCT07076121	Oct 2025 → May 2029 expected	pancreatic ductal adenocarcinoma	Bristol-Myers Squibb	Active not recruiting	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2/3	NCT07063745 Comparator	Jan 2026 → Aug 2031 expected	—	Bristol-Myers Squibb	Recruiting	No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

Field	Value	Cited text
Known as	BMS-986504	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07602946 ↗ 10 NCT07077434 ↗ NCT06883747 ↗ NCT07532902 ↗ NCT07549022 ↗ NCT06855771 ↗ NCT07063745 ↗ NCT06672523 ↗ NCT07492680 ↗ NCT07283705 ↗ NCT07594626 ↗
Known as	MTA-cooperative PRMT5 Inhibitor BMS-986504	“MTA-cooperative PRMT5 Inhibitor BMS-986504” NCT07594626 ↗
Known as	Navlimetostat	“Navlimetostat (BMS-986504)” NCT07063745 ↗ 3 NCT07579221 ↗ NCT07076121 ↗ NCT07544628 ↗
Action	Inhibit	“MTA cooperative PRMT5 inhibitor” NCT06883747 ↗
Route	Oral	“single oral dose of radiolabeled \[14C\]-BMS-986504” NCT06672523 ↗
Target	PRMT5	“MTA cooperative PRMT5 inhibitor” NCT06883747 ↗